Phathom Pharmaceuticals Inc (NASDAQ: PHAT) is -51.23% lower on its value in year-to-date trading and has touched a low of $3.81 and a high of $19.71 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The PHAT stock was last observed hovering at around $3.90 in the last trading session, with the day’s gains setting it 0.06%.
Currently trading at $3.96, the stock is -21.52% and -25.40% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.07 million and changing 1.54% at the moment leaves the stock -62.08% off its SMA200. PHAT registered -58.23% loss for a year compared to 6-month loss of -75.62%. The firm has a 50-day simple moving average (SMA 50) of $5.3084 and a 200-day simple moving average (SMA200) of $10.44285.
The stock witnessed a -36.44% gain in the last 1 month and extending the period to 3 months gives it a -41.68%, and is -14.47% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 9.14% over the week and 12.38% over the month.
Phathom Pharmaceuticals Inc (PHAT) has around 427 employees, a market worth around $275.76M and $55.25M in sales. Profit margin for the company is -605.09%. Distance from 52-week low is 3.94% and -79.91% from its 52-week high. The company has generated returns on investments over the last 12 months (-118.94%).
with sales reaching $29.02M over the same period.The EPS is expected to grow by 24.67% this year, but quarterly earnings will post 195.71% year-over-year. Quarterly sales are estimated to grow 1,417.56% in year-over-year returns.
Phathom Pharmaceuticals Inc (PHAT) Top Institutional Holders
204.0 institutions hold shares in Phathom Pharmaceuticals Inc (PHAT), with institutional investors hold 100.86% of the company’s shares. The shares outstanding are 68.52M, and float is at 38.70M with Short Float at 33.36%. Institutions hold 97.00% of the Float.
The top institutional shareholder in the company is FRAZIER LIFE SCIENCES MANAGEMENT, L.P. with over 10.11 million shares valued at $104.13 million. The investor’s holdings represent 17.2637% of the PHAT Shares outstanding. As of 2024-06-30, the second largest holder is MEDICXI VENTURES MANAGEMENT (JERSEY) LTD with 7.46 million shares valued at $76.89 million to account for 12.7473 of the shares outstanding. The other top investors are CARLYLE GROUP INC. which holds 3.5 million shares representing 5.9715% and valued at over $35.84 million, while INVESCO LTD. holds 5.3853 of the shares totaling 3.14 million with a market value of $32.38 million.
Phathom Pharmaceuticals Inc (PHAT) Insider Activity
The most recent transaction is an insider sale by Henderson Molly, the company’s CFO and CBO. SEC filings show that Henderson Molly sold 3,678 shares of the company’s common stock on Apr 07 ’25 at a price of $4.55 per share for a total of $16740.0. Following the sale, the insider now owns 89868.0 shares.
Phathom Pharmaceuticals Inc disclosed in a document filed with the SEC on Mar 13 ’25 that Parikh Asit (Director) bought a total of 10,000 shares of the company’s common stock. The trade occurred on Mar 13 ’25 and was made at $4.42 per share for $44200.0. Following the transaction, the insider now directly holds 85500.0 shares of the PHAT stock.
Still, SEC filings show that on Jan 21 ’25, Henderson Molly (CFO and CBO) disposed off 6,583 shares at an average price of $6.59 for $43371.0. The insider now directly holds 93,546 shares of Phathom Pharmaceuticals Inc (PHAT).
